Gilead Taps New Talent In China Hepatitis Drug Access Drive

In signs of a strategy shift, Gilead Sciences appears to be independently pursuing opportunities in China's rapidly growing hepatitis market by appointing a top market access executive.

capsules

More from Business

More from Scrip